Revolutionizing Duchenne Research with Briya’s Dynamic Dataset

Accelerate breakthroughs in Duchenne Muscular Dystrophy with comprehensive, real-world data insights.

Request Your Dataset Now

The Briya Duchenne Dataset includes:

Over 110 patient records
Over 110,000 data points
Over 3,500 encounters across 5 different sites
Clinical Scales: Quality of Life Measures (PedsQL, DMD-QoL), Clinical Severity Scales (Vignos Scale, Brooke Scale)
Imaging data: Muscle MRI (T1-weighted and T2-weighted imaging, Muscle fat fraction analysis, Muscle atrophy and fibrosis), Echocardiography (Left ventricular size and function, Fibrosis presence in the myocardium)
Doctor’s notes
Lab tests: Genetic Testing (Dystrophin Gene Mutation Testing), Muscle Enzymes (CK Levels, LDH)
Functional Assessments: Motor Function Measures (6MWT, NSAA, PUL, Brooke Upper Extremity Scale, Time to Stand/Climb/Run), Pulmonary Function Tests (FVC, PEF, MIP/MEP), Cardiac Function (Echocardiograms, Cardiac MRI
Number of procedures
Co-morbidities

Understanding Duchenne: Challenges in Diagnosis and Treatment

Duchenne Muscular Dystrophy (DMD) is a rare, progressive genetic disorder that primarily affects boys, causing severe muscle degeneration and loss of function. Affecting approximately 1 in 3,500 male births worldwide, it is one of the most prevalent genetic conditions. While advancements in genetic testing have improved diagnosis rates in recent years, the combination of a small patient population and significant genetic variability results in limited patient data. This scarcity of data hinders large-scale studies, impeding a deeper understanding of the disease’s complex progression and slowing the development of standardized treatment plans.

Currently, there is no cure for DMD. Modern treatments aim to improve the quality of life by slowing symptom progression, often through the use of glucocorticoids and physical therapy. Robust real-world data has the potential to be a game-changer, optimizing and accelerating the development of innovative, life-changing therapies.

Briya’s Dynamic Dataset addresses the barriers to understanding and treating Duchenne by unlocking critical insights into disease causation, progression, and treatment outcomes. Functional assessments, imaging data, and laboratory tests, including Dystrophin Gene Mutation Testing, provide a comprehensive view of the patient journey, revealing potential correlations and causations. Our expertly curated data empowers researchers to enhance clinical trials by identifying eligible patient populations, optimize care pathways for personalized treatments, and accelerate drug development through the discovery of new therapies and biomarkers.